Tonix Pharmaceuticals (NASDAQ:TNXP) Shares Down 2.6% – Time to Sell?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)’s stock price was down 2.6% on Friday . The stock traded as low as $0.22 and last traded at $0.23. Approximately 16,568,814 shares changed hands during trading, a decline of 74% from the average daily volume of 62,617,117 shares. The stock had previously closed at $0.24.

Analyst Ratings Changes

Separately, StockNews.com began coverage on Tonix Pharmaceuticals in a research note on Friday. They issued a “hold” rating for the company.

Tonix Pharmaceuticals Trading Up 1.3 %

The company’s 50 day simple moving average is $0.26 and its two-hundred day simple moving average is $0.31. The stock has a market cap of $44.48 million, a price-to-earnings ratio of 0.00 and a beta of 2.02. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million during the quarter, compared to analysts’ expectations of $2.63 million. Research analysts expect that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.